David A. Scott

Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2

David C. Hoaglin, Neil Hawkins, Jeroen P. Jansen et al. · Value in Health · 2011 · 767 citations · Full text

Public Health, Biostatistics, Comparative Effectiveness Research +15

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial

Beth Woods, Neil Hawkins, David A. Scott · BMC Medical Research Methodology · 2010 · 298 citations · Full text

Public Health, Biostatistics, Epidemiologic Methods +12

Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

Melanie J. Davies, Stephen C. Bain, Stephen L. Atkin et al. · Diabetes Care · 2015 · 228 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 227 citations · Full text

Medicine, Cardiology, Pharmacology +14